Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
VJHemOnc was the official media partner of the 2nd SOHO Italy 2020 Virtual Meeting which took place on the 22-24th of September 2020.
This virtual three-day meeting brought together leading SOHO experts and Italian researchers in acute leukemias, MPNs, and MDS, with the aims of consolidating the Italian Hematology-SOHO partnership.
Watch the meeting on-demand below!
Day One
Day one of the meeting featured sessions on acute lymphoblastic leukemia (ALL).
- ALL: State of the art in MD Anderson Cancer Center: Hagop Kantarjian
- ALL: State of the art in Europe: Giovanni Martinelli
- Optimizing adult and elderly frontline ALL therapy: Role of immunochemotherapy: Elias Jabbour
- ALL: Ph-like and new genetic subtypes and treatment implications: Marina Konopleva
- CAR T-cells therapy: novel generation, fast-off, dual CAR T-cells: Josep-Maria Ribera
- Novel therapeutic strategies on acute leukemia based on synthetic lethality: Andrea Ghelli Luserna di Rorà
- Diagnostic approaches for Ph-like B-ALL: Sergej Konoplev
- Morphology in acute leukemias and hematologic malignancies: Gina Zini
- Monoclonal antibodies: real-life and new combination trials: Cristina Papayannidis
- Novel monoclonal antibodies combinations and near future of ALL in Italy: Francesco Lanza
Day Two
Day two of the meeting featured sessions on acute myeloid leukemia (AML).
- ALL: State of the art in MD Anderson Cancer Center: Hagop Kantarjian
- ALL: State of the art in Europe: Giovanni Martinelli
- Optimizing adult and elderly frontline ALL therapy: Role of immunochemotherapy: Elias Jabbour
- ALL: Ph-like and new genetic subtypes and treatment implications: Marina Konopleva
- CAR T-cells therapy: novel generation, fast-off, dual CAR T-cells: Josep-Maria Ribera
- Novel therapeutic strategies on acute leukemia based on synthetic lethality: Andrea Ghelli Luserna di Rorà
- Diagnostic approaches for Ph-like B-ALL: Sergej Konoplev
- Morphology in acute leukemias and hematologic malignancies: Gina Zini
- Monoclonal antibodies: real-life and new combination trials: Cristina Papayannidis
- Novel monoclonal antibodies combinations and near future of ALL in Italy: Francesco Lanza
Day Three
Day three of the meeting featured sessions on multiple myeloma (MM), lymphoma, chronic myeloid leukemia (CML), myeloproliferative neoplasms (MPNs), and myelodysplastic disorders (MDS).
- ALL: State of the art in MD Anderson Cancer Center: Hagop Kantarjian
- ALL: State of the art in Europe: Giovanni Martinelli
- Optimizing adult and elderly frontline ALL therapy: Role of immunochemotherapy: Elias Jabbour
- ALL: Ph-like and new genetic subtypes and treatment implications: Marina Konopleva
- CAR T-cells therapy: novel generation, fast-off, dual CAR T-cells: Josep-Maria Ribera
- Novel therapeutic strategies on acute leukemia based on synthetic lethality: Andrea Ghelli Luserna di Rorà
- Diagnostic approaches for Ph-like B-ALL: Sergej Konoplev
- Morphology in acute leukemias and hematologic malignancies: Gina Zini
- Monoclonal antibodies: real-life and new combination trials: Cristina Papayannidis
- Novel monoclonal antibodies combinations and near future of ALL in Italy: Francesco Lanza
